Tuesday’s Midday Movers: Anthera Pharmaceuticals (ANTH), ImmunoCellular Therapeutics (IMUC), Fuelcell Energy (FCEL), Acura Pharmaceuticals (ACUR), Can-Fite BioPharma (CANF)

By Carrie Williams

So far Tuesday, May 21, NASDAQ is up 0.62% and the S&P is up 0.63%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Anthera Pharmaceuticals (ANTHResearch Report), ImmunoCellular Therapeutics (IMUCResearch Report), Fuelcell Energy (FCELResearch Report), Acura Pharmaceuticals (ACURResearch Report) and Can-Fite BioPharma (CANFResearch Report).

Anthera Pharmaceuticals is up 35.05% in midday trading to $0.08. Shares opened today at $0.06. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

ImmunoCellular Therapeutics is down -19.2% in midday trading to $0.02. Shares opened today at $0.03. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

Fuelcell Energy is down -15.77% in midday trading to $1.26. Shares opened today at $1.49. The company has a 52-week low of $1.04 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $21.00, marking a 1309.40% potential upside from current levels. In a report issued on March 8, Cowen analyst Jeff Osborne maintained a Buy rating on FCEL, with a price target of $33, which represents a potential upside of 2115% from where the stock is currently trading. Separately, on March 7, Craig-Hallum’s Eric Stine downgraded the stock to Hold and has a price target of $6.

See today’s analyst top recommended stocks >>

Acura Pharmaceuticals is down -12% in midday trading to $0.13. Shares opened today at $0.15. The company has a 52-week low of $0.06 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

Can-Fite BioPharma is up 7.76% in midday trading to $3.47. Shares opened today at $3.22. The company has a 52-week low of $2.91 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $30.00, marking a 831.68% potential upside from current levels. In a report issued on May 9, H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on CANF, with a price target of $30, which represents a potential upside of 832% from where the stock is currently trading.

Trending Stocks Based on Insider Activity >>